Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86148 trials found · Page 66 of 4308
-
New CAR t therapy targets Hard-to-Treat myeloma in phase 2 trial
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Phase: PHASE2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Apr 25, 2026 04:26 UTC
-
Experimental immune cell therapy tested against aggressive brain cancer
Disease control TerminatedThis is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.
Phase: PHASE1 • Sponsor: Yang Zhang • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
One-Time gene therapy aims to free patients from lifelong blood transfusions
Disease control ENROLLING_BY_INVITATIONThe goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating β-thalassemia.
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
New drug duo battles recurrent ovarian cancer in major global trial
Disease control Recruiting nowThis study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Apr 15, 2026 16:16 UTC
-
New CAR T-Cell therapy shows promise for tough blood cancers
Disease control OngoingThe goal of this clinical study is to learn more about KTE-X19, and how safe and effective it is in adult Japanese participants with relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) or r/r B-precursor Acute Lymphoblastic Leukemia (B-ALL). The primary objectives of this study…
Phase: PHASE2 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 25, 2026 04:28 UTC
-
Chilling babies to save their brains: major trial tests cooling for newborn injury
Disease control Recruiting nowThe goal of this randomised control trial is to establish the safety and efficacy of whole-body hypothermia for babies with mild hypoxic ischaemic encephalopathy, inform national and international guidelines, and establish uniform practice across the NHS. The main questions it a…
Phase: PHASE3 • Sponsor: Imperial College London • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Gene therapy trial offers hope for inherited blindness
Disease control OngoingThis study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR muta…
Phase: PHASE2, PHASE3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Apr 24, 2026 16:18 UTC
-
Magic mushroom compound tested as depression treatment
Disease control OngoingApproximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybi…
Phase: PHASE3 • Sponsor: Usona Institute • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Targeted radiation zaps early prostate cancer spread, aims to delay harsh hormone therapy
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will pro…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Scientists test new 'Living Drug' to fight aggressive lymphoma
Disease control Recruiting nowThe goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational…
Phase: PHASE1, PHASE2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New drug combo aims to free CML patients from lifelong pills
Disease control Recruiting nowTo evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Phase: PHASE2 • Sponsor: Korean Society of Hematology • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
New shot aims to cut heart attacks in those with 'Silent' cholesterol risk
Disease control OngoingThe purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
New targeted drug enters final testing for Tough-to-Treat stomach cancers
Disease control Recruiting nowThe purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Custom-Made cancer vaccine trial seeks to train immune system
Disease control Recruiting nowThis clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
New Alzheimer's drug aims to slow memory loss in major trial
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Phase: PHASE2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC
-
New hope for Tough-to-Treat breast cancer: major trial tests promising drug
Disease control Recruiting nowThe aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 p…
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New hope for keeping breast cancer at bay after surgery
Disease control Recruiting nowThe purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice pati…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New Two-Pronged immunotherapy tested to shrink tumors before surgery
Disease control OngoingThis is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety, tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the perioperative p…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Experimental gene therapy targets devastating childhood epilepsy
Disease control OngoingWAYFINDER is a Phase 1/2 study in Australia to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet syndrome aged 6 to \<84 months. The study follows an open-label, dose-escalation design.
Phase: PHASE1, PHASE2 • Sponsor: Encoded Therapeutics • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC